Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Nektar Therapeutics ( (NKTR) ) is now available.
On April 21, 2026, Nektar Therapeutics priced an upsized underwritten public offering of 3,532,609 shares of common stock at $92.00 per share, with underwriters exercising in full a 30-day option for an additional 529,891 shares the following day. The company expects to raise about $350.9 million in net proceeds when the offering, sold entirely by Nektar under an effective shelf registration, closes on April 23, 2026, subject to customary conditions.
The capital injection is earmarked for general corporate purposes, notably research and development and clinical work, including Phase 3 trials of rezpegaldesleukin in atopic dermatitis and alopecia areata, as well as manufacturing to advance its pipeline. The upsized deal, led by Jefferies, TD Cowen, Piper Sandler and Citigroup, strengthens Nektar’s balance sheet as it pushes its lead immunotherapy candidate toward late-stage development, with potential implications for its competitive position in autoimmune and inflammatory disease markets.
The most recent analyst rating on (NKTR) stock is a Hold with a $95.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
NKTR scores as a balanced, higher-risk biotech: strong technical momentum and a constructive clinical/strategic narrative with improved funding support the score, but they are meaningfully offset by weak financial performance driven by ongoing losses, declining recent-year revenue, and substantial cash burn.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics is a San Francisco–based clinical-stage biotechnology company developing therapies to correct immunological dysfunction in autoimmune and chronic inflammatory diseases. Its lead candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a first-in-class regulatory T cell stimulator in Phase 2 and 2b trials for atopic dermatitis, alopecia areata and Type 1 diabetes, alongside additional preclinical immunology programs.
Average Trading Volume: 1,224,134
Technical Sentiment Signal: Buy
Current Market Cap: $2.91B
See more insights into NKTR stock on TipRanks’ Stock Analysis page.